Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRA_10762 is a synthetic small molecule belonging to the class of phenylbenzimidazoles, characterized by a chemical structure containing both phenyl and benzimidazole moieties[1][2]. It has the molecular formula C20H15ClN4O[2]. CRA_10762 functions as an inhibitor of trypsin 1 (also known as serine protease 1 or PRSS1), binding to its active site and thereby inhibiting its enzymatic activity[5][7]. This compound has been studied primarily in structural biology contexts for its interaction with trypsin, but there is no evidence it has advanced into clinical development or therapeutic use. Its primary relevance appears to be as a biochemical tool compound for studying serine protease inhibition rather than as a pharmaceutical agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CRA_10762.